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Abstract
Methyl-CpG-binding protein 2 (MeCP2), encoded by the gene MECP2, is a transcriptional regulator and chromatin-
remodeling protein, which is ubiquitously expressed and plays an essential role in the development and maintenance
of the central nervous system (CNS). Highly enriched in post-migratory neurons, MeCP2 is needed for neuronal
maturation, including dendritic arborization and the development of synapses. Loss-of-function mutations in MECP2
cause Rett syndrome (RTT), a debilitating neurodevelopmental disorder characterized by a phase of normal
development, followed by the progressive loss of milestones and cognitive disability. While a great deal has been
discovered about the structure, function, and regulation of MeCP2 in the time since its discovery as the genetic
cause of RTT, including its involvement in a number of RTT-related syndromes that have come to be known as
MeCP2-spectrum disorders, much about this multifunctional protein remains enigmatic. One unequivocal fact that has
become apparent is the importance of maintaining MeCP2 protein levels within a narrow range, the limits of which
may depend upon the cell type and developmental time point. As such, MeCP2 is amenable to complex, multifactorial
regulation. Here, we summarize the role of the MECP2 3' untranslated region (UTR) in the regulation of MeCP2 protein
levels and how mutations in this region contribute to autism and other non-RTT neuropsychiatric disorders.
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Introduction
In 1999, Huda Zoghbi and her colleagues discovered that
MECP2, which codes for methyl-CpG-binding protein 2
(MeCP2), is the gene that is mutated in Rett syndrome
(RTT) [1]. It is now known from a decade and a half of
study that MeCP2 is a multifunctional protein that plays a
complex, yet essential role, in the development and main-
tenance of the central nervous system (CNS). The diversity
of MeCP2 function includes, but may not be limited to: tran-
scription regulation [2–4], chromatin-remodeling and his-
tone modification [5–7], and regulation of messenger RNA
(mRNA)-splicing [8, 9] and microRNA (miRNA)-processing
[10]. These molecular functions manifest themselves on a
cellular level in ways that are not completely understood but
ultimately result in proper neural cell differentiation [11],
neuronal maturation [12–14], dendritic arborization and
spine formation [15–17], and adequate production of synap-
tic proteins and receptors [18, 19]. Moreover, MeCP2 exerts
both cell autonomous and non-cell autonomous effects on
neurons [20]. Once thought to be exclusive to neurons in the
CNS, we now also know that glial cells, including astrocytes
and oligodendrocytes, express MeCP2 and require it to ad-
equately support the morphological and functional develop-
ment of neurons. In turn, glial cells have been implicated as
key players in the pathophysiology of RTT and MeCP2-
related disorders [21–25].
In most cases, loss of MeCP2 function in females results
in classic RTT [26]. RTT is an X-linked neurodevelopmen-
tal disorder that is characterized by 6–18 months of normal
development, followed by a stagnation and eventual regres-
sion of developmental milestones. Affected individuals ex-
hibit a myriad of characteristic signs and debilitating
symptoms, including microcephaly, intellectual disability,
autistic features, overall growth retardation and weight loss,
hypotonia, loss of motor coordination, autonomic dysfunc-
tion, breathing irregularities and apneas, and replacement
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of purposeful hand movements with stereotypies such as
wringing, clapping, or flapping [27, 28]. In males, RTT-
causing mutations most often result in severe neonatal en-
cephalopathy [29, 30]; however, in rare cases, these same
mutations can cause classic RTT in males with Klinefelter
syndrome (47, XXY) or somatic mosaicism [31, 32]. Loss-
of-function mutations that do not cause RTT produce a
host of neuropsychiatric abnormalities in both males (e.g.,
mental retardation, bipolar disorder, schizophrenia, PPM-
X syndrome) [30, 33–36] and females (e.g., atypical RTT,
mental retardation, Angelman-like syndrome, autism)
[37–41]. In addition, increases in MeCP2 dosage also lead
to profound dysfunction. Duplications of the gene locus
results in MeCP2 duplication syndrome, which is a pro-
gressive neurodevelopmental disorder with RTT-like fea-
tures that occurs most often in males [42, 43].
While it is intriguing that dramatic losses and gains in the
MECP2 gene dosage both result in a similar, debilitating
phenotype, it has also been demonstrated that a hypomorphic
MECP2 allele that expresses 50 % of the wild type gene level
also produces an RTT-like syndrome in mice [44], thus dem-
onstrating a need for MeCP2 protein levels to be maintained
within a narrow margin to ensure proper neurological devel-
opment. Accordingly, there is also evidence thatMeCP2 levels
are reduced in other neurodevelopmental disorders, including
autism, trisomy 21, fragile X syndrome, Angelman syndrome,
and Prader-Willi syndrome [37, 45]. Therefore, it is not sur-
prising thatMECP2 expression is subject to intense, complex
regulation at virtually every level from DNA to protein. While
the overall expression patterns for MeCP2 in the developing
nervous system has been elucidated, there is not always a
clear correlation between mRNA and protein expression,
and the various and complex mechanisms governing the
transcript-protein balance are not completely understood
[12, 13, 37, 46–50]. The clinical relevance for elucidating
these processes is particularly crucial, not only for provid-
ing a more complete understanding of the heterogeneity in
the clinical presentation and treatment potential of RTT
and related MeCP2-spectrum disorders, but also for those
above-mentioned developmental disorders in which
MeCP2 expression is dysregulated in the absence of an
obvious mutation. In this review, we will summarize the
current understanding of the spatio-temporal expression
patterns of MeCP2 throughout brain development, as
well as the regulatory mechanisms that control the speci-
ficity of these patterns, focusing on the regulatory poten-
tial of the highly conserved 3′ untranslated region (3′
UTR). We will seek to establish the 3′UTR as an import-
ant potential contributor in establishing and maintaining
homeostatic levels of MeCP2 expression in a develop-
mentally appropriate manner. Finally, we will discuss the
clinical relevance of these regulatory mechanisms as they
are currently understood and their implications for po-
tential therapeutic strategies.
MECP2 expression
During development, MeCP2 protein is expressed at low
levels throughout the brain prenatally but progressively
increases with neurogenesis and reaches its peak in ma-
ture, post-migratory neurons [12, 13]. The timing of
MeCP2 expression varies by brain region and cell type
and correlates closely with the maturation of the given
cell type and matches the overall ontogenetic maturation
pattern of the CNS [49], i.e., older structures, such as
the spinal cord and brain stem, become MeCP2 positive
before newer structures, such as the cerebral cortex,
hippocampus, and cerebellum [50]. This temporal pat-
tern holds within individual brain regions—e.g., in the
cortex, the timing of MeCP2 expression follows the
inside-out lamination sequence, with Cajal-Retzius cells
becoming positive first, followed by early-born deep-
layer neurons, and finally later-born superficial-layer
neurons [12]. This suggests that the MeCP2 protein only
becomes detectable once the individual neuron reaches
a certain point of maturity and is consistent with the
hypothesis that MeCP2 plays an important role in main-
taining neuronal maturation. Additionally, in the cortex,
hippocampus, and the granule cells of the cerebellum,
MeCP2 expression is most closely correlated with synap-
togenesis, consistent with its proposed role in the forma-
tion and maintenance of synapses [50].
In addition to the spatio-temporal dependence of the
MECP2 expression, the brain contains a heterogeneous
cell population, including both low MeCP2-expressing
cells (MeCP2lo) and high MeCP2-expressing cells (MeC-
P2hi), displaying a defined distribution pattern. MeCP2lo
cells are present in the highest proportion in the granular
layer of the cerebellum, whereas layer IV of the cerebral
cortex and the molecular layer of the cerebellum exhibit a
higher proportion of MeCP2hi cells. The remaining layers
of both regions contain roughly equal proportions of each
cell type. The proportion of MeCP2-positive neurons
increases throughout postnatal life, and it correlates with
the percentage of MeCP2hi cells, indicating a possibly
increasing need for MeCP2 function as the nervous sys-
tem matures [46].
Alternative splicing generates two MeCP2 isoforms,
MeCP2_e1 and MeCP2_e2, which only differ at their N-
termini. Isoform E1 is 498 amino acids long and is trans-
lated from exons 1, 3, and 4, whereas isoform E2 is 486
amino acids and translated from exons 2, 3, and 4 [51, 52]
(Fig. 1a). These isoforms are also spatio-temporally reg-
ulated. The e1 isoform is much more abundant in the
brain and also demonstrates more widespread expres-
sion throughout development. Early in postnatal life,
the e2 transcript is widely expressed but with time
becomes largely restricted to the dorsal thalamus and
cortical layer V [53]. Consistent with this, a more re-
cent report utilized an MeCP2E1-specific antibody to
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demonstrate that the E1 protein is also widely expressed,
with its highest expression in the cortex and cerebellum,
and it is also expressed in high amounts in neurons as
compared to astrocytes [54].
It is evident that very intricate regulation is required to
achieve the temporal, regional, and cell-population specifi-
city of these expression patterns, and we will now turn
our attention to the evidence implicating the 3′UTR as an
important contributor to the fine-tuning of homeostatic
MeCP2 expression levels throughout development.
3′ untranslated region (3′UTR) of MECP2
Structure and conservation
The MECP2 gene contains a remarkably large, highly
conserved 3′UTR. Coy et al. [55] screened cosmid
clones with radioactively labeled cDNA clones they
had isolated from human tissue samples and identi-
fied a long contig with no open reading frame or in-
trons. They mapped the contig to the 3′UTR of
MECP2, and further investigation revealed that alter-
native polyadenylation (poly A) signals could origin-
ate transcripts of multiple lengths. Reichwald et al.
[56] similarly found by comparative sequence ana-
lysis the existence of this additional stretch of
sequence 3′ to the previously reported poly(A) site,
which terminated in an alternative poly(A) site. In
addition, Coy et al. [55] compared the entire human
3′UTR sequence with the mouse sequence and found
that homology of this region of the MECP2 gene
(~52 %) is lower than the average for 3′UTRs. How-
ever, they discovered blocks of sequence within the 3′
UTR that were highly conserved, not only in mouse
but also kangaroo, rat, hamster, macaque, and chim-
panzee sequences. These regions were also predicted
to have high minimum free energy, suggesting a weak
secondary structure. Conversely, the regions of the 3′
UTR that were not highly similar in primary sequence
were predicted to have low minimum free energy, sug-
gesting tight folding. Indeed, the free-energy distribu-
tion over the entire sequence was highly similar
between human and mouse, suggesting that the overall
secondary structure of the 3′UTR was conserved
throughout evolution regardless of divergent primary
structures between different species and therefore may
confer important regulatory functions. Likewise, the
loose conformation of the highly conserved regions of
sequence suggests that these may represent important
binding sites for transregulatory elements. Taken to-
gether, such evolutionary analysis emphasizes the im-
portance of the 3′UTR on a very fundamental level.
Fig. 1 Regulation via the MECP2 3'UTR. a Schematic depicting the cis-acting regulatory elements in the genomic sequence of the MECP2
3'UTR. Open boxes indicate the silencer and enhancer described by Liu and Francke [59]. Closed, colored boxes indicate auxiliary elements
involved in polyadenylation, as described by Newnham et al. [58]. E exon, GRS G-rich element, USE upstream sequence element. b Four
unique MECP2 transcripts produced by alternative polyadenylation. c Relative position of putative miRNA binding sites in the 3'UTR of the
10.2-kb species of MECP2 mRNA, as defined by Target Scan. This representation is limited to predicted sites for miRNAs that are broadly conserved
in vertebrates (with the exception of the human-specific site for miR-483-5p)
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Alternative polyadenylation of MECP2
Alternative poly(A) sites within the 3′UTR can be
used to generate four mRNA transcripts of varying
length: ~1.8, ~5.4, ~7.5, and ~10.2 kb (Fig. 1b) [57].
Studies have revealed that the distribution and abundance
of each transcript varies by tissue and is developmentally
regulated. The 10.2-kb transcript is the most abundant in
the brain, and in sharp contrast to MeCP2 protein, the
expression of this transcript is highly enriched in the em-
bryonic brain but then progressively declines during post-
natal development [37, 47], only to be upregulated again
in the adult brain [37]. It has been suggested that this
decrease in the use of the long 3′UTR transcript accounts
for the corresponding increase in MeCP2 protein levels
via possible differential regulation conferred by the indi-
vidual transcripts. However, Samaco et al. [37] found that,
while total MECP2 transcript expression levels across
neuronal populations decreased from the fetal to the post-
natal stage, the increase in MeCP2 protein expression,
along with an increase in the percentage of MeCP2hi cells
with age, correlates with an increase in the expression of
both the total and the long variant MECP2 transcripts
within the MeCP2hi population. Additionally, they noted a
significant decrease in expression of the long MECP2
transcript within the MeCP2lo population in postnatal
brains versus fetal brain and of the ratio of long transcript
to total transcripts, which later increased in adult brains.
However, the study found no significant correlation
between transcript length and MeCP2 protein levels on a
single cell level. This highlights how the alternative polya-
denylation of the MECP2 3′UTR serves as a dynamic
source of brain region and even cell-type-specific regula-
tion of MeCP2 expression. While we do not currently fully
understand how each individual transcript relates to pro-
tein expression, and how this may change with spatio-
temporal context, the heterogeneity of the levels of tran-
script type among cell populations suggests that the 3′
UTR may be important for fine-tuning MeCP2 protein
expression to meet the homeostatic needs of individual
microenvironments in the brain.
Alternative poly(A) is determined both by the presence
of pairs of cis-acting core sequences that specify the site
of poly(A) as well as auxiliary regulatory elements that
can facilitate or repress poly(A) at a designated site.
Newnham et al. [58] discovered such cis regulatory ele-
ments both upstream and downstream of the binding
sites for cleavage and polyadenylation specificity factor
(CPSF) in the MECP2 3′UTR. They discovered a G-rich
element (GRS) downstream of the most proximal
poly(A) core sequence (Fig. 1a), the mutation of which
resulted in significantly reduced efficiency of polyadeny-
lation. They also showed that this site is specifically
bound by hnRNP F, a protein involved in the 3′ end for-
mation, indicating it likely plays an important regulatory
role in the production of alternative MECP2 transcripts.
They also found an element upstream of the most distal
poly(A) signal, which was very similar to upstream se-
quence elements (USEs; Fig. 1a) found in human colla-
gen genes and human COX-2. Mutation at this site also
reduced polyadenylation efficiency, albeit to a lesser ex-
tent. Interestingly, the DNA sequence of the 3′UTR also
harbors enhancer and repression elements that act dir-
ectly on the MECP2 core promoter (Fig. 1a). These
regulatory elements were shown by gel shift assays to
bind nuclear proteins, presumably transcription factors
[59]. Additional evidence is needed in order to tease out
the mechanisms by which these cis elements regulate
the transcription and post-transcriptional modification
of MECP2. Insight into how alternative polyadenylation
of MECP2 is regulated, for example, may shed light on
the circumstances under which one transcript is re-
quired over another in order to meet the homeostatic
needs of the cell.
The complicated nature of the relationship between the
length of the MECP2 3′UTR and the expression of the
MeCP2 protein is likely due to the complex and multifac-
torial impact of 3′UTR on gene expression. The 3′UTR
can play a role in translation efficiency, localization, and
the folding and stability of the mRNA [60]. As such, alter-
native poly(A) offers the ability of the cell to “customize” a
transcript to meet its needs. That is, cleaving the tran-
script at varying poly(A) sites varies the regulatory ele-
ments at the level of both the primary and secondary
structure, which in turn will affect the stability,
localization, translatability, etc. of the mRNA. As such,
mutations in the 3′UTR certainly have the potential to
affect the stability of MECP2 transcripts, and indeed, aut-
istic patients carrying non-RTT-causing mutations in con-
served sequences of theMECP2 3′UTR displayed reduced
levels of MECP2 mRNA compared to controls [61]. Given
the fine balance of the MeCP2 expression needed for
brain development, this is potentially of high clinical
significance.
microRNAs (miRNAs) and post-transcriptional regulation of
MeCP2
One feature of 3′UTRs that is often of particular interest
is the presence of targeting sequences for trans-acting
regulatory elements. Among these regulatory elements are
miRNAs, which are short, non-coding RNA molecules
that are involved in post-transcriptional gene regulation.
miRNAs function by base-pairing with a complementary
sequence on target messenger RNA (mRNA). This base-
pairing is most often imperfect, with exact matching
occurring only between nucleotides 2 and 8 (known as the
“seed region”) of the miRNA and a complementary se-
quence in the 3′UTR of the target mRNA [62–64]. This
type of partial-binding of miRNA to its target usually
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results in either translational repression [65], deadenyla-
tion [66], or, more rarely, cleavage of the mRNA [67].
miRNAs have also been shown to establish mRNA thresh-
old levels, below which protein translation is highly re-
duced, thus allowing for a fine-tuning of gene expression
levels in addition to overt gene-silencing [68]. miRNAs
regulate gene expression in the developing nervous system
[69], with roles in regulating neurogenesis [70, 71], neur-
onal maturation, spinogenesis, dendritic arborization [72],
synaptogenesis [73], and neuronal survival [74]. This has
profound implications for how miRNA misexpression
may affect cognitive capability. For example, Hansen et al.
[75] showed that moderate increases in miR-132 in the
hippocampus enhanced cognitive capacity, while supra-
physiological expression resulted in impaired cognition
and an increase in dendritic spines, implying that the de-
creased capacity for learning and memory resulted from
alterations in the structure of synaptic connections.
In line with this, MECP2 is regulated by several miR-
NAs (Table 1), and its 3′UTR contains putative target
sequences for many more (Fig. 1c); however, the role of
miRNAs in regulating MECP2 expression is diverse and
complex. These promiscuous molecules serve as im-
portant potential modifiers for local, tissue-, or possibly
even cell-type-specific fine-tuning of MeCP2 protein
levels, either developmentally or in response to cellular
activity. In the nervous system, miRNA-132 has been
demonstrated to regulate MeCP2 expression in a
homeostatic feedback loop with brain-derived neuro-
trophic factor (BDNF) [76]. BDNF is a known target of
MeCP2, which interacts directly with its promoter to
enhance its expression [77]. Klein et al. [76] demon-
strated that activation of the cAMP response element-
binding protein (CREB) pathway in cortical neurons
stimulated an increase in miR-132 expression and sub-
sequent reduction in MeCP2 expression. Blocking miR-
132 increased the expression of both MeCP2 and
BDNF, while siRNA-mediated knockdown of MeCP2
reduced both BDNF and miR-132 levels, suggesting a
potential CREB-mediated regulatory feedback loop
(Fig. 2). miR-212, which is closely related to and genet-
ically arranged in tandem with miR-132, and which has
been shown to reduce MeCP2 levels in gastric carcin-
oma cell lines [78], participates in a similar negative
feedback loop with MeCP2 in the dorsal striatum [79].
This miR-212-MeCP2 relationship was also shown to have
regulatory implications for BDNF, specifically under the
conditions of extended cocaine exposure [79]. Chen and
colleagues [80] also demonstrated that MeCP2 is a func-
tional target of miR-7b, which is in turn targeted and si-
lenced by MeCP2 as postnatal neurons mature, suggesting
another homeostatic regulatory loop. In addition, Han et
al. [81] identified a novel, human-specific targeting site for
miR-483-5p in the long MECP2 3′UTR. They postulated
a potential role for this miRNA in fetal development by
demonstrating an inverse correlation between elevated
miR-483-5p levels and decreased MeCP2 expression levels
in human fetal brains. Furthermore, regulation of MeCP2
by miR-124a in the spinal cord may modulate nociception.
Kynast et al. [82] demonstrated that peripheral noxious
stimulation in mice led to a decrease in miR-124a
expression in neurons of the dorsal horn, accompanied by
an increase in MeCP2 and pro-inflammatory genes, as
well as nociceptive behavior.
The relevance of studying the role of miRNAs in regu-
lating MECP2 is highlighted further by evidence that
miRNAs modulate MECP2 expression in physiological
processes other than neurogenesis. For example, target-
ing of MECP2 by miR-22 has been shown to promote
smooth muscle cell differentiation [83] and to reduce
apoptosis in ischemic cardiomyocytes [84]. Future stud-
ies investigating brain-region-specific miRNAs and their
potential to target MECP2 may provide additional
insight into the enigmatic relationship between tran-
script variants and MeCP2 protein expression in differ-
ent parts of the brain.
Table 1 miRNAs that are known to target the MECP2 3'UTR and the reported biological significance for each
microRNA Biological relevance Reference
miR-132 Homeostatic regulation of MeCP2 and BDNF. Klein et al. (2007) [76]
Reduction of miR-132 during ischemic-preconditioning contributes to elevated MeCP2 levels in the
cortex following ischemic injury.
Lusardi et al. (2010) [94]
miR-212 Differential regulation of MeCP2 and BDNF in response to prolonged cocaine intake. Im et al. (2010) [79]
miR-7b Homeostatic regulation of MeCP2 during postnatal development. Chen et al. (2014)
miR-483-5p Human-specific regulation of MeCP2 expression during fetal development. Han et al. (2013) [81]
miR-124a May attenuate nociception by repressing MeCP2 and, by extension, downstream pro-inflammatory genes. Kynast et al. (2013) [82]
miR-22 MeCP2-targeting during ischemic-preconditioning reduces apoptosis and cardiac fibrosis. Feng et al. (2014) [84]
Smooth muscle cell differentiation. Zhao et al. (2015) [83]
miR-511 Only binds MECP2 3'UTR carrying C > T SNP. Reduces peripheral MeCP2 expression by ~50 % and
has implications for aggression.
Tantra et al. (2014) [93]
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Clinical implications of the MECP2 3′UTR beyond RTT
In addition to those causing RTT and related disorders,
MECP2 mutations have been described in other neuro-
developmental disorders, such as autism, and X-linked
mental retardation [33, 34, 61, 85, 86]. Some of these
mutations occur in the 3′UTR rather than in the coding
sequence, in accordance with a need for finely tuned
regulation of MeCP2 protein levels for proper neuro-
logical function. Coutinho et al. [61] found 21 variations
in the MECP2 3′UTR of 46 out of 172 autistic patients.
Of these variations, 12 did not occur in controls. They
also found that MECP2 mRNA levels in peripheral blood
mononuclear cells of four patients with variations in
conserved sequences were significantly lower than that
of controls, suggesting that changes in at least these con-
served sequences may alter mRNA stability and, thus, pro-
tein expression levels. Shibayama et al. [86] also found
two 3′UTR variations in autistic patients, as well as one
variation in a patient with ADHD. While these alterations
seem to be most common to autism [61, 86–88], they
have also been found in patients with spontaneous intel-
lectual disability [88–90], as well as individuals with atyp-
ical RTT, or classic RTT with no detectable pathological
mutation in the MECP2 coding sequence [88, 91]. Muta-
tions in the 3′UTR of MECP2 were also found in a rare
number of patients with RTT in a study by Santos and
colleagues [88]; however, none of the five variants they
discovered are found in the putative protein-targeting sites
of the UTR; additionally, two had been previously
described as polymorphisms, one was present in an un-
affected father and another was present in an unaffected
mother, suggesting that they are not pathogenic, particu-
larly in the case of the father. A summary of theseMECP2
3′UTR variants and their pathological relevance can be
found in Table 2. Taken together, these findings suggest
that mutations in the 3′UTR, which would purportedly
impact the expression of MeCP2 rather than its function,
may not cause full-blown RTT, except in rare cases, but
could still impair neurological function given a context
allowing for MeCP2 dysregulation.
In line with this, Hanchard et al. [92] reported an
adult male harboring a partial MECP2 duplication,
who was high functioning and able to live independ-
ently despite suffering from epilepsy and cognitive
impairment. The duplication included all four exons
but excluded almost the entire 3′UTR. Given the im-
portance of the 3′UTR for the stability and activity of
the MeCP2 protein, the loss of the 3′UTR in the du-
plicated segment of the MECP2 gene more likely mit-
igates the MeCP2 overexpression and, by extension,
the severity of symptoms. Additionally, Samaco et al.
[37] demonstrated differences in MeCP2 expression levels
in autism, pervasive developmental disorder, Prader-Willi
syndrome, and Angelman syndrome; by laser-scanning cy-
tometry, the disturbances in MeCP2 expression were de-
termined as due to differential transcriptional and post-
transcriptional mechanisms.
miRNA-targeting of the 3′UTR of MECP2 has also
been implicated in neurological dysfunction. Human-
specific miR-483-5p, which has been shown to decrease
MeCP2 expression, is transcribed from the second in-
tron of the genetically imprinted gene insulin-like
growth factor 2 (IGF2). IGF2 expression occurs almost
exclusively from the paternal allele, and imprinting de-
fects that lead to expression from the maternal allele
cause Beckwith-Wiedemann syndrome (BWS). The
study demonstrates that BWS patients with bi-allelic
expression of IGF2 also overexpress miR-483-5p and
underexpress MeCP2. This finding may have implica-
tions for the etiology of higher prevalence of autism in
these patients [81]. Additionally, a recent study by Tan-
tra et al. showed that a 50 % overexpression of MeCP2
influences aggression levels in opposing ways in two
different strains of mice. To test this interaction be-
tween genetic background and expression level in
humans, they demonstrated that miR-511, which is
expressed in the brain, binds selectively to MECP2
mRNA transcripts that carry a C > T SNP in the 3′
UTR. As a result, T carriers have a ~50 % reduction in
peripheral MeCP2 expression. The C allele at this locus
is associated with increased aggression in schizophre-
nia, thus implicating the interaction between altered
MeCP2 expression and genetic background as a poten-
tial mechanism [93]. Increased expression of MeCP2
resulting from reduction of miR-132-mediated repres-
sion has also been implicated in the neuroprotective
response to pending ischemic injury [94].
These examples highlight how the 3′UTR may
serve as a potential source for pathogenic misregula-
tion of MeCP2, and as such, it may be worthwhile to
conduct additional studies investigating the potential
Fig. 2 MeCP2 participates in homeostatic feedback loops involving
regulation by miRNAs. An example of several feedback mechanisms
involving BDNF is depicted here
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pathogenicity of mutations and polymorphisms in
this critical region.
Conclusions
In summary, regulation of MeCP2 expression is com-
plex, multifactorial, and crucial for the proper mainten-
ance and function of the CNS. In this review, we have
focused our attention on the role of the MECP2 3′UTR
in this process. Evidence suggests that the 3′UTR con-
fers multiple levels of regulation on MeCP2 expression
that are significant for neurological function. This is
consistent with the role of the 3′UTR as seen in other
important neural proteins. For example, poly(A) pro-
duces two BDNF transcripts, with a long or short 3′
UTR. The long 3′UTR represses translation at rest,
while the short transcript is actively translated. However,
upon neuronal activation, the long transcript, but not
the short, undergoes rapid translational activation [95].
Likewise, BDNF is also regulated by miRNAs via its 3′
UTR [96].
Post-transcriptional regulation by the 3′UTR offers
the advantage of rapid and precise homeostatic control
over protein levels in response to a cell’s individual
needs. However, the complexity of this single avenue of
gene regulation highlights the need for intense study, es-
pecially given the fact that a vast array of additional
mechanisms exist that manage the expression and func-
tion of MeCP2 at every level. For example, the MECP2
core promoter is located within a CpG island [56], and
gene expression levels have been shown to inversely cor-
relate with methylation. In fact, hypermethylation of the
MECP2 core promoter has been observed in autistic pa-
tients [97]. Additionally, Liu and Francke [59] identified
four enhancers and two silencers within the gene; these
enhancers contain predicted binding sites for brain-
specific transcription factors, and three of them were
able to act in cis with the core promoter. MeCP2 also
exists in two isoforms, the alternate expression of which
appears to be dependent upon differential methylation
of regulatory elements within the MECP2 promoter,
which can be manipulated with decitabine [96]. In
addition to tight control over expression, mechanisms
such as post-translational modification also contribute
to the regulation of MeCP2 activity. For example, activ-
ity-dependent phosphorylation of threonine 308 blocks
the interaction of MeCP2’s repressor domain with
NCoR, which attenuates its transcriptional repression
[98]. The advances in understanding the complex and
interactive nature of MECP2 and its regulatory ele-
ments are pivotal to unraveling the mechanisms under-
pinning the development and progression of complex
and poorly understood neurodevelopmental disorders
Table 2 Sequence variations in the MECP2 3'UTR that have been reported in non-RTT neurological disorders, atypical RTT, or RTT
without a detectable pathogenic coding region mutation
Nucleotide change Disease Notes Reference
c.*98insA 1. ADHD 1. Shibayama et al. (2004) [86]
2. ID 2. Tejada (2006) [29]
3. PMD delay, ID, autism 3. Santos et al. (2008) [88]
c.*177G > C Autism Shibayama et al. (2004) [86]
c.*5348T > C Autism Shibayama et al. (2004) [86]
c.*93G > A ID Reported in two patients; one also had an intronic
variation.
Ylisaukko-oja et al. (2005) [90]
c.*139G > A Autism with regression Xi et al. (2007) [87]
c. *371G > C Autism Occurs in conserved sequence in patient with reduced
MECP2 mRNA levels.
Coutinho et al. (2007) [61]
c.*554G > A Autism Occurs in conserved sequence in patient with reduced
MECP2 mRNA levels.
Coutinho et al. (2007) [61]
c.*2556T > A Autism Occurs in conserved sequence in patient with reduced
MECP2 mRNA levels.
Coutinho et al. (2007) [61]
c.*2956G > A Autism Occurs in conserved sequence in patient with reduced
MECP2 mRNA levels.
Coutinho et al. (2007) [61]
c.*9G > A Atypical RTT with ID and
autism
No coding MECP2 mutation. Santos et al. (2008) [88]
c.*8500C > G;
*8503delC
ID, ataxia, epilepsy C > G variant inherited from unaffected father, deletion
from mother.
Santos et al. (2008) [88]
c.473C > T; *14G > A Atypical RTT Missense mutation in MBD combined with 3'UTR variation Santos et al. (2008) [88]
c.*92C > G RTT Non-coding MECP2 mutation Fendri-Kriaa et al. (2010) [91]
ID intellectual disability, PMD psychomotor development, MBD methyl-CpG-binding domain
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and to devise novel therapeutic approaches. miRNAs
in particular are attractive therapeutic targets, as there
is evidence that their expression can be modified by
small molecules [99]. Likewise, methods are being de-
veloped to deliver miRNA mimics and/or inhibitors
directly into the CNS (e.g., lipid-, polyethylenimine-,
and dendrimer-based methods) [100].
Finally, the bulk of the literature exploring the expres-
sion, regulation, and function of MeCP2 has focused
almost exclusively on neurons, as early studies were not
able to show any expression in glial cells. Recently, in-
creasing attention has been pointed at the role played by
glial cells in conditioning the morphological and func-
tional development of neurons, and several studies are
deciphering the specific roles of glia in neurodevelop-
ment, as well as in RTT and related disorders. However,
the relative paucity of information regarding how
MeCP2 is regulated in non-neuronal brain cells is a gap
that needs to be filled by further investigations.
Abbreviations
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polyadenylation specificity factor ; GRS: G-rich element ; USE: Upstream
sequence element ; BDNF: Brain derived neurotrophic factor; CREB: cAMP
response element-binding protein; IGF2: Insulin-like growth factor 2 ;




HM researched and wrote the manuscript. ZPP edited and critically evaluated
the manuscript. Both authors read and approved the final manuscript.
Acknowledgements
We want to thank the support from NIH-NINDS F31NS084551 NRSA predoctoral
fellowship and the Jérôme LeJeune Foundation.
Received: 1 May 2015 Accepted: 18 September 2015
References
1. Amir RE, Van den Veyver IB, Wan M, Tran CQ, Francke U, Zoghbi HY. Rett
syndrome is caused by mutations in X-linked MECP2, encoding methyl-
CpG-binding protein 2. Nat Genet. 1999;23(2):185–8. doi:10.1038/13810.
2. Nan X, Campoy FJ, Bird A. MeCP2 is a transcriptional repressor with
abundant binding sites in genomic chromatin. Cell. 1997;88(4):471–81.
3. Chahrour M, Jung SY, Shaw C, Zhou X, Wong ST, Qin J, et al. MeCP2, a key
contributor to neurological disease, activates and represses transcription.
Science. 2008;320(5880):1224–9. doi:10.1126/science.1153252.
4. Li Y, Wang H, Muffat J, Cheng AW, Orlando DA, Loven J, et al. Global
transcriptional and translational repression in human-embryonic-stem-cell-
derived Rett syndrome neurons. Cell Stem Cell. 2013;13(4):446–58.
doi:10.1016/j.stem.2013.09.001.
5. Jones PL, Veenstra GJ, Wade PA, Vermaak D, Kass SU, Landsberger N, et al.
Methylated DNA and MeCP2 recruit histone deacetylase to repress
transcription. Nat Genet. 1998;19(2):187–91. doi:10.1038/561.
6. Nan X, Ng HH, Johnson CA, Laherty CD, Turner BM, Eisenman RN, et al.
Transcriptional repression by the methyl-CpG-binding protein MeCP2
involves a histone deacetylase complex. Nature. 1998;393(6683):386–9.
doi:10.1038/30764.
7. Nikitina T, Ghosh RP, Horowitz-Scherer RA, Hansen JC, Grigoryev SA,
Woodcock CL. MeCP2-chromatin interactions include the formation of
chromatosome-like structures and are altered in mutations causing Rett
syndrome. J Biol Chem. 2007;282(38):28237–45. doi:10.1074/jbc.M704304200.
8. Young JI, Hong EP, Castle JC, Crespo-Barreto J, Bowman AB, Rose MF, et al.
Regulation of RNA splicing by the methylation-dependent transcriptional
repressor methyl-CpG binding protein 2. Proc Natl Acad Sci U S A.
2005;102(49):17551–8. doi:10.1073/pnas.0507856102.
9. Maunakea AK, Chepelev I, Cui K, Zhao K. Intragenic DNA methylation
modulates alternative splicing by recruiting MeCP2 to promote exon
recognition. Cell Res. 2013;23(11):1256–69. doi:10.1038/cr.2013.110.
10. Cheng TL, Wang Z, Liao Q, Zhu Y, Zhou WH, Xu W, et al. MeCP2
suppresses nuclear microRNA processing and dendritic growth by
regulating the DGCR8/Drosha complex. Dev Cell. 2014;28(5):547–60.
doi:10.1016/j.devcel.2014.01.032.
11. Gao H, Bu Y, Wu Q, Wang X, Chang N, Lei L, et al. Mecp2 regulates neural
cell differentiation by suppressing the Id1 to Her2 axis in zebrafish. J Cell
Sci. 2015;128(12):2340–50. doi:10.1242/jcs.167874.
12. Shahbazian MD, Antalffy B, Armstrong DL, Zoghbi HY. Insight into Rett
syndrome: MeCP2 levels display tissue- and cell-specific differences and
correlate with neuronal maturation. Hum Mol Genet. 2002;11(2):115–24.
13. Kishi N, Macklis JD. MECP2 is progressively expressed in post-migratory
neurons and is involved in neuronal maturation rather than cell fate decisions.
Mol Cell Neurosci. 2004;27(3):306–21. doi:10.1016/j.mcn.2004.07.006.
14. Matarazzo V, Cohen D, Palmer AM, Simpson PJ, Khokhar B, Pan SJ, et al. The
transcriptional repressor Mecp2 regulates terminal neuronal differentiation.
Mol Cell Neurosci. 2004;27(1):44–58. doi:10.1016/j.mcn.2004.05.005.
15. Chapleau CA, Calfa GD, Lane MC, Albertson AJ, Larimore JL, Kudo S, et al.
Dendritic spine pathologies in hippocampal pyramidal neurons from Rett
syndrome brain and after expression of Rett-associated MECP2 mutations.
Neurobiol Dis. 2009;35(2):219–33. doi:10.1016/j.nbd.2009.05.001.
16. Landi S, Putignano E, Boggio EM, Giustetto M, Pizzorusso T, Ratto GM. The
short-time structural plasticity of dendritic spines is altered in a model of
Rett syndrome. Sci Rep. 2011;1:45. doi:10.1038/srep00045.
17. Stuss DP, Boyd JD, Levin DB, Delaney KR. MeCP2 mutation results in
compartment-specific reductions in dendritic branching and spine density
in layer 5 motor cortical neurons of YFP-H mice. PLoS One.
2012;7(3):e31896. doi:10.1371/journal.pone.0031896.
18. Blue ME, Naidu S, Johnston MV. Development of amino acid receptors in
frontal cortex from girls with Rett syndrome. Ann Neurol.
1999;45(4):541–5.
19. Colantuoni C, Jeon OH, Hyder K, Chenchik A, Khimani AH, Narayanan V,
et al. Gene expression profiling in postmortem Rett Syndrome brain:
differential gene expression and patient classification. Neurobiol Dis.
2001;8(5):847–65. doi:10.1006/nbdi.2001.0428.
20. Kishi N, Macklis JD. MeCP2 functions largely cell-autonomously, but also
non-cell-autonomously, in neuronal maturation and dendritic arborization
of cortical pyramidal neurons. Exp Neurol. 2010;222(1):51–8. doi:10.1016/
j.expneurol.2009.12.007.
21. Ballas N, Lioy DT, Grunseich C, Mandel G. Non-cell autonomous influence of
MeCP2-deficient glia on neuronal dendritic morphology. Nat Neurosci.
2009;12(3):311–7. doi:10.1038/nn.2275.
22. Maezawa I, Swanberg S, Harvey D, LaSalle JM, Jin LW. Rett syndrome astrocytes
are abnormal and spread MeCP2 deficiency through gap junctions. J Neurosci.
2009;29(16):5051–61. doi:10.1523/JNEUROSCI.0324-09.2009.
23. Lioy DT, Garg SK, Monaghan CE, Raber J, Foust KD, Kaspar BK, et al. A role for
glia in the progression of Rett’s syndrome. Nature. 2011;475(7357):497–500.
doi:10.1038/nature10214.
24. Derecki NC, Cronk JC, Lu Z, Xu E, Abbott SB, Guyenet PG, et al. Wild-type
microglia arrest pathology in a mouse model of Rett syndrome. Nature.
2012;484(7392):105–9. doi:10.1038/nature10907.
25. Nguyen MV, Felice CA, Du F, Covey MV, Robinson JK, Mandel G, et al.
Oligodendrocyte lineage cells contribute unique features to Rett syndrome
neuropathology. J Neurosci. 2013;33(48):18764–74. doi:10.1523/
JNEUROSCI.2657-13.2013.
26. Wan M, Lee SS, Zhang X, Houwink-Manville I, Song HR, Amir RE, et al. Rett
syndrome and beyond: recurrent spontaneous and familial MECP2
mutations at CpG hotspots. Am J Hum Genet. 1999;65(6):1520–9.
doi:10.1086/302690.
27. Hagberg B, Aicardi J, Dias K, Ramos O. A progressive syndrome of
autism, dementia, ataxia, and loss of purposeful hand use in girls: Rett’s
syndrome: report of 35 cases. Ann Neurol. 1983;14(4):471–9. doi:10.1002/
ana.410140412.
McGowan and Pang Cell Regeneration  (2015) 4:9 Page 8 of 10
28. Nomura Y. Early behavior characteristics and sleep disturbance in Rett
syndrome. Brain Dev. 2005;27 Suppl 1:S35–42. doi:10.1016/
j.braindev.2005.03.017.
29. Imessaoudene B, Bonnefont JP, Royer G, Cormier-Daire V, Lyonnet S, Lyon
G, et al. MECP2 mutation in non-fatal, non-progressive encephalopathy in a
male. J Med Genet. 2001;38(3):171–4.
30. Zeev BB, Yaron Y, Schanen NC, Wolf H, Brandt N, Ginot N, et al. Rett
syndrome: clinical manifestations in males with MECP2 mutations. J Child
Neurol. 2002;17(1):20–4.
31. Budden SS, Dorsey HC, Steiner RD. Clinical profile of a male with Rett syndrome.
Brain Dev. 2005;27 Suppl 1:S69–71. doi:10.1016/j.braindev.2005.03.018.
32. Maiwald R, Bonte A, Jung H, Bitter P, Storm Z, Laccone F, et al. De novo
MECP2 mutation in a 46, XX male patient with Rett syndrome.
Neurogenetics. 2002;4(2):107–8.
33. Meloni I, Bruttini M, Longo I, Mari F, Rizzolio F, D’Adamo P, et al. A mutation
in the Rett syndrome gene, MECP2, causes X-linked mental retardation and
progressive spasticity in males. Am J Hum Genet. 2000;67(4):982–5.
doi:10.1086/303078.
34. Orrico A, Lam C, Galli L, Dotti MT, Hayek G, Tong SF, et al. MECP2 mutation
in male patients with non-specific X-linked mental retardation. FEBS Lett.
2000;481(3):285–8.
35. Cohen D, Lazar G, Couvert P, Desportes V, Lippe D, Mazet P, et al. MECP2
mutation in a boy with language disorder and schizophrenia. Am J
Psychiatry. 2002;159(1):148–9.
36. Klauck SM, Lindsay S, Beyer KS, Splitt M, Burn J, Poustka A. A mutation hot
spot for nonspecific X-linked mental retardation in the MECP2 gene
causes the PPM-X syndrome. Am J Hum Genet. 2002;70(4):1034–7.
doi:10.1086/339553.
37. Samaco RC, Nagarajan RP, Braunschweig D, LaSalle JM. Multiple pathways
regulate MeCP2 expression in normal brain development and exhibit
defects in autism-spectrum disorders. Hum Mol Genet. 2004;13(6):629–39.
doi:10.1093/hmg/ddh063.
38. Lam CW, Yeung WL, Ko CH, Poon PM, Tong SF, Chan KY, et al. Spectrum of
mutations in the MECP2 gene in patients with infantile autism and Rett
syndrome. J Med Genet. 2000;37(12):E41.
39. Carney RM, Wolpert CM, Ravan SA, Shahbazian M, Ashley-Koch A, Cuccaro
ML, et al. Identification of MeCP2 mutations in a series of females with
autistic disorder. Pediatr Neurol. 2003;28(3):205–11.
40. Watson P, Black G, Ramsden S, Barrow M, Super M, Kerr B, et al.
Angelman syndrome phenotype associated with mutations in MECP2, a
gene encoding a methyl CpG binding protein. J Med Genet.
2001;38(4):224–8.
41. Milani D, Pantaleoni C, D’Arrigo S, Selicorni A, Riva D. Another patient with
MECP2 mutation without classic Rett syndrome phenotype. Pediatr Neurol.
2005;32(5):355–7. doi:10.1016/j.pediatrneurol.2004.12.012.
42. Van Esch H, Bauters M, Ignatius J, Jansen M, Raynaud M, Hollanders K, et al.
Duplication of the MECP2 region is a frequent cause of severe mental
retardation and progressive neurological symptoms in males. Am J Hum
Genet. 2005;77(3):442–53. doi:10.1086/444549.
43. del Gaudio D, Fang P, Scaglia F, Ward PA, Craigen WJ, Glaze DG, et al.
Increased MECP2 gene copy number as the result of genomic duplication
in neurodevelopmentally delayed males. Genet Med. 2006;8(12):784–92. doi:
10.109701.gim.0000250502.28516.3c.
44. Samaco RC, Fryer JD, Ren J, Fyffe S, Chao HT, Sun Y, et al. A partial loss of
function allele of methyl-CpG-binding protein 2 predicts a human
neurodevelopmental syndrome. Hum Mol Genet. 2008;17(12):1718–27.
doi:10.1093/hmg/ddn062.
45. Zhang A, Shen CH, Ma SY, Ke Y, El Idrissi A. Altered expression of
autism-associated genes in the brain of Fragile X mouse model.
Biochem Biophys Res Commun. 2009;379(4):920–3. doi:10.1016/
j.bbrc.2008.12.172.
46. LaSalle JM, Goldstine J, Balmer D, Greco CM. Quantitative localization of
heterogeneous methyl-CpG-binding protein 2 (MeCP2) expression
phenotypes in normal and Rett syndrome brain by laser scanning
cytometry. Hum Mol Genet. 2001;10(17):1729–40.
47. Balmer D, Goldstine J, Rao YM, LaSalle JM. Elevated methyl-CpG-binding
protein 2 expression is acquired during postnatal human brain
development and is correlated with alternative polyadenylation. J Mol Med.
2003;81(1):61–8. doi:10.1007/s00109-002-0396-5.
48. Jung BP, Jugloff DG, Zhang G, Logan R, Brown S, Eubanks JH. The
expression of methyl CpG binding factor MeCP2 correlates with cellular
differentiation in the developing rat brain and in cultured cells. J Neurobiol.
2003;55(1):86–96. doi:10.1002/neu.10201.
49. Cassel S, Revel MO, Kelche C, Zwiller J. Expression of the methyl-CpG-
binding protein MeCP2 in rat brain. An ontogenetic study. Neurobiol Dis.
2004;15(2):206–11. doi:10.1016/j.nbd.2003.10.011.
50. Mullaney BC, Johnston MV, Blue ME. Developmental expression of methyl-
CpG binding protein 2 is dynamically regulated in the rodent brain.
Neuroscience. 2004;123(4):939–49.
51. Mnatzakanian GN, Lohi H, Munteanu I, Alfred SE, Yamada T, MacLeod PJ,
et al. A previously unidentified MECP2 open reading frame defines a new
protein isoform relevant to Rett syndrome. Nat Genet. 2004;36(4):339–41.
doi:10.1038/ng1327.
52. Kriaucionis S, Bird A. The major form of MeCP2 has a novel N-terminus
generated by alternative splicing. Nucleic Acids Res. 2004;32(5):1818–23.
doi:10.1093/nar/gkh349.
53. Dragich JM, Kim YH, Arnold AP, Schanen NC. Differential distribution of the
MeCP2 splice variants in the postnatal mouse brain. J Comp Neurol.
2007;501(4):526–42. doi:10.1002/cne.21264.
54. Zachariah RM, Olson CO, Ezeonwuka C, Rastegar M. Novel MeCP2 isoform-
specific antibody reveals the endogenous MeCP2E1 expression in murine
brain, primary neurons and astrocytes. PLoS One. 2012;7(11):e49763.
doi:10.1371/journal.pone.0049763.
55. Coy JF, Sedlacek Z, Bachner D, Delius H, Poustka A. A complex pattern of
evolutionary conservation and alternative polyadenylation within the long
3”-untranslated region of the methyl-CpG-binding protein 2 gene (MeCP2)
suggests a regulatory role in gene expression. Hum Mol Genet.
1999;8(7):1253–62.
56. Reichwald K, Thiesen J, Wiehe T, Weitzel J, Poustka WA, Rosenthal A,
et al. Comparative sequence analysis of the MECP2-locus in human and
mouse reveals new transcribed regions. Mamm Genome.
2000;11(3):182–90.
57. Pelka GJ, Watson CM, Christodoulou J, Tam PP. Distinct expression profiles
of Mecp2 transcripts with different lengths of 3’UTR in the brain and
visceral organs during mouse development. Genomics. 2005;85(4):441–52.
doi:10.1016/j.ygeno.2004.12.002.
58. Newnham CM, Hall-Pogar T, Liang S, Wu J, Tian B, Hu J, et al. Alternative
polyadenylation of MeCP2: influence of cis-acting elements and trans-acting
factors. RNA Biol. 2010;7(3):361–72.
59. Liu J, Francke U. Identification of cis-regulatory elements for MECP2
expression. Hum Mol Genet. 2006;15(11):1769–82. doi:10.1093/hmg/ddl099.
60. Decker CJ, Parker R. Diversity of cytoplasmic functions for the 3’
untranslated region of eukaryotic transcripts. Curr Opin Cell Biol.
1995;7(3):386–92.
61. Coutinho AM, Oliveira G, Katz C, Feng J, Yan J, Yang C, et al. MECP2
coding sequence and 3’UTR variation in 172 unrelated autistic patients.
Am J Med Genet B Neuropsychiatr Genet. 2007;144B(4):475–83.
doi:10.1002/ajmg.b.30490.
62. Lewis BP, Shih IH, Jones-Rhoades MW, Bartel DP, Burge CB. Prediction of
mammalian microRNA targets. Cell. 2003;115(7):787–98.
63. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by
adenosines, indicates that thousands of human genes are microRNA
targets. Cell. 2005;120(1):15–20. doi:10.1016/j.cell.2004.12.035.
64. Wang XJ, Reyes JL, Chua NH, Gaasterland T. Prediction and identification of
Arabidopsis thaliana microRNAs and their mRNA targets. Genome Biol.
2004;5(9):R65. doi:10.1186/gb-2004-5-9-r65.
65. Williams AE. Functional aspects of animal microRNAs. Cell Mol Life Sci.
2008;65(4):545–62. doi:10.1007/s00018-007-7355-9.
66. Bazzini AA, Lee MT, Giraldez AJ. Ribosome profiling shows that miR-430
reduces translation before causing mRNA decay in zebrafish. Science.
2012;336(6078):233–7. doi:10.1126/science.1215704.
67. Kawasaki H, Taira K. MicroRNA-196 inhibits HOXB8 expression in myeloid
differentiation of HL60 cells. Nucleic Acids Symp Ser (Oxf). 2004;48:211–2.
doi:10.1093/nass/48.1.211.
68. Mukherji S, Ebert MS, Zheng GX, Tsang JS, Sharp PA, van Oudenaarden A.
MicroRNAs can generate thresholds in target gene expression. Nat Genet.
2011;43(9):854–9. doi:10.1038/ng.905.
69. Yoo AS, Staahl BT, Chen L, Crabtree GR. MicroRNA-mediated switching of
chromatin-remodelling complexes in neural development. Nature.
2009;460(7255):642–6. doi:10.1038/nature08139.
70. Liu C, Zhao X. MicroRNAs in adult and embryonic neurogenesis.
Neuromolecular Med. 2009;11(3):141–52. doi:10.1007/s12017-009-8077-y.
McGowan and Pang Cell Regeneration  (2015) 4:9 Page 9 of 10
71. Volvert ML, Rogister F, Moonen G, Malgrange B, Nguyen L. MicroRNAs tune
cerebral cortical neurogenesis. Cell Death Differ. 2012;19(10):1573–81.
doi:10.1038/cdd.2012.96.
72. Schratt GM, Tuebing F, Nigh EA, Kane CG, Sabatini ME, Kiebler M, et al. A
brain-specific microRNA regulates dendritic spine development. Nature.
2006;439(7074):283–9. doi:10.1038/nature04367.
73. Edbauer D, Neilson JR, Foster KA, Wang CF, Seeburg DP, Batterton MN,
et al. Regulation of synaptic structure and function by FMRP-associated
microRNAs miR-125b and miR-132. Neuron. 2010;65(3):373–84.
doi:10.1016/j.neuron.2010.01.005.
74. Vo NK, Cambronne XA, Goodman RH. MicroRNA pathways in neural
development and plasticity. Curr Opin Neurobiol. 2010;20(4):457–65.
doi:10.1016/j.conb.2010.04.002.
75. Hansen KF, Karelina K, Sakamoto K, Wayman GA, Impey S, Obrietan K.
miRNA-132: a dynamic regulator of cognitive capacity. Brain Struct Funct.
2013;218(3):817–31. doi:10.1007/s00429-012-0431-4.
76. Klein ME, Lioy DT, Ma L, Impey S, Mandel G, Goodman RH. Homeostatic
regulation of MeCP2 expression by a CREB-induced microRNA. Nat
Neurosci. 2007;10(12):1513–4. doi:10.1038/nn2010.
77. Chen WG, Chang Q, Lin Y, Meissner A, West AE, Griffith EC, et al. Derepression
of BDNF transcription involves calcium-dependent phosphorylation of MeCP2.
Science. 2003;302(5646):885–9. doi:10.1126/science.1086446.
78. Wada R, Akiyama Y, Hashimoto Y, Fukamachi H, Yuasa Y. miR-212 is
downregulated and suppresses methyl-CpG-binding protein MeCP2 in human
gastric cancer. Int J Cancer. 2010;127(5):1106–14. doi:10.1002/ijc.25126.
79. Im HI, Hollander JA, Bali P, Kenny PJ. MeCP2 controls BDNF expression and
cocaine intake through homeostatic interactions with microRNA-212. Nat
Neurosci. 2010;13(9):1120–7. doi:10.1038/nn.2615.
80. Chen Y, Shin BC, Thamotharan S, Devaskar SU. Differential methylation
of the micro-RNA 7b gene targets postnatal maturation of murine
neuronal Mecp2 gene expression. Dev Neurobiol. 2014;74(4):407–25.
doi:10.1002/dneu.22126.
81. Han K, Gennarino VA, Lee Y, Pang K, Hashimoto-Torii K, Choufani S,
et al. Human-specific regulation of MeCP2 levels in fetal brains by
microRNA miR-483-5p. Genes Dev. 2013;27(5):485–90. doi:10.1101/
gad.207456.112.
82. Kynast KL, Russe OQ, Moser CV, Geisslinger G, Niederberger E. Modulation
of central nervous system-specific microRNA-124a alters the inflammatory
response in the formalin test in mice. Pain. 2013;154(3):368–76.
doi:10.1016/j.pain.2012.11.010.
83. Zhao H, Wen G, Huang Y, Yu X, Chen Q, Afzal TA, et al. MicroRNA-22
regulates smooth muscle cell differentiation from stem cells by targeting
methyl CpG-binding protein 2. Arterioscler Thromb Vasc Biol.
2015;35(4):918–29. doi:10.1161/ATVBAHA.114.305212.
84. Feng Y, Huang W, Wani M, Yu X, Ashraf M. Ischemic preconditioning
potentiates the protective effect of stem cells through secretion of
exosomes by targeting Mecp2 via miR-22. PLoS One. 2014;9(2):e88685.
doi:10.1371/journal.pone.0088685.
85. Dotti MT, Orrico A, De Stefano N, Battisti C, Sicurelli F, Severi S, et al. A Rett
syndrome MECP2 mutation that causes mental retardation in men.
Neurology. 2002;58(2):226–30.
86. Shibayama A, Cook Jr EH, Feng J, Glanzmann C, Yan J, Craddock N,
et al. MECP2 structural and 3’-UTR variants in schizophrenia, autism and
other psychiatric diseases: a possible association with autism. Am J Med
Genet B Neuropsychiatr Genet. 2004;128B(1):50–3. doi:10.1002/
ajmg.b.30016.
87. Xi CY, Ma HW, Lu Y, Zhao YJ, Hua TY, Zhao Y, et al. MeCP2 gene mutation
analysis in autistic boys with developmental regression. Psychiatr Genet.
2007;17(2):113–6. doi:10.1097/YPG.0b013e3280114a5c.
88. Santos M, Yan J, Temudo T, Oliveira G, Vieira JP, Fen J, et al. Analysis of
highly conserved regions of the 3’UTR of MECP2 gene in patients with
clinical diagnosis of Rett syndrome and other disorders associated with
mental retardation. Dis Markers. 2008;24(6):319–24.
89. Tejada MI, Penagarikano O, Rodriguez-Revenga L, Martinez-Bouzas C, Garcia
B, Badenas C, et al. Screening for MECP2 mutations in Spanish patients with
an unexplained mental retardation. Clin Genet. 2006;70(2):140–4.
doi:10.1111/j.1399-0004.2006.00647.x.
90. Ylisaukko-Oja T, Rehnstrom K, Vanhala R, Kempas E, von Koskull H,
Tengstrom C, et al. MECP2 mutation analysis in patients with mental
retardation. Am J Med Genet A. 2005;132A(2):121–4. doi:10.1002/
ajmg.a.30416.
91. Fendri-Kriaa N, Mkaouar-Rebai E, Moalla D, Belguith N, Louhichi N, Zemni R,
et al. Mutational analysis of the MECP2 gene in Tunisian patients with Rett
syndrome: a novel double mutation. J Child Neurol. 2010;25(8):1042–6.
doi:10.1177/0883073809356353.
92. Hanchard NA, Carvalho CM, Bader P, Thome A, Omo-Griffith L, del Gaudio
D, et al. A partial MECP2 duplication in a mildly affected adult male: a
putative role for the 3’ untranslated region in the MECP2 duplication
phenotype. BMC Med Genet. 2012;13:71. doi:10.1186/1471-2350-13-71.
93. Tantra M, Hammer C, Kastner A, Dahm L, Begemann M, Bodda C, et al. Mild
expression differences of MECP2 influencing aggressive social behavior.
EMBO Mol Med. 2014;6(5):662–84. doi:10.1002/emmm.201303744.
94. Lusardi TA, Farr CD, Faulkner CL, Pignataro G, Yang T, Lan J, et al. Ischemic
preconditioning regulates expression of microRNAs and a predicted target,
MeCP2, in mouse cortex. J Cereb Blood Flow Metab. 2010;30(4):744–56.
doi:10.1038/jcbfm.2009.253.
95. Lau AG, Irier HA, Gu J, Tian D, Ku L, Liu G, et al. Distinct 3’UTRs differentially
regulate activity-dependent translation of brain-derived neurotrophic
factor (BDNF). Proc Natl Acad Sci U S A. 2010;107(36):15945–50.
doi:10.1073/pnas.1002929107.
96. Varendi K, Matlik K, Andressoo JO. From microRNA target validation to
therapy: lessons learned from studies on BDNF. Cell Mol Life Sci.
2015;72(9):1779–94. doi:10.1007/s00018-015-1836-z.
97. Nagarajan RP, Hogart AR, Gwye Y, Martin MR, LaSalle JM. Reduced MeCP2
expression is frequent in autism frontal cortex and correlates with aberrant
MECP2 promoter methylation. Epigenetics. 2006;1(4):e1–11.
98. Ebert DH, Gabel HW, Robinson ND, Kastan NR, Hu LS, Cohen S, et al. Activity-
dependent phosphorylation of MeCP2 threonine 308 regulates interaction
with NCoR. Nature. 2013;499(7458):341–5. doi:10.1038/nature12348.
99. Broderick JA, Zamore PD. MicroRNA therapeutics. Gene Ther.
2011;18(12):1104–10. doi:10.1038/gt.2011.50.
100. Zhang Y, Wang Z, Gemeinhart RA. Progress in microRNA delivery. J Controlled
Release. 2013;172(3):962–74. doi:10.1016/j.jconrel.2013.09.015.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
McGowan and Pang Cell Regeneration  (2015) 4:9 Page 10 of 10
